Shots:
- Starpharma has entered into a collaboration & license agreement with Genentech to develop dendrimer-drug conjugates incorporating Genentech’s drugs for oncology targets, leveraging Starpharma’s DEP drug delivery tech
- As per the deal, Genentech will receive an exclusive global license under Starpharma’s IP to develop & commercialize collaboration-derived products, potentially multiple per target, in exchange for $5.5M upfront & ~$564M in development, commercial, & net sales milestones, with tiered royalties on global sales
- DEP platform enhances drug development by improving solubility, efficacy, PK, & toxicity profiles, offering benefits across a wide range of drug classes
Ref: GlobeNewsWire| Image: Starpharma and Genentech | Press Release
Related News:- Avant Technologies and Austrianova Form Joint Venture Klothonova to Develop Klotho-Based Cell Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
